Hélène F.E. Gleitz

781 total citations
15 papers, 248 citations indexed

About

Hélène F.E. Gleitz is a scholar working on Genetics, Hematology and Physiology. According to data from OpenAlex, Hélène F.E. Gleitz has authored 15 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Hematology and 6 papers in Physiology. Recurrent topics in Hélène F.E. Gleitz's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Lysosomal Storage Disorders Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Hélène F.E. Gleitz is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Lysosomal Storage Disorders Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Hélène F.E. Gleitz collaborates with scholars based in Netherlands, Germany and United Kingdom. Hélène F.E. Gleitz's co-authors include Brian Bigger, Rebecca Holley, Claire O’Leary, Rebekka K. Schneider, Zelpha D’Souza, Gabriella Forte, James Cook, Helen Parker, Aiyin Liao and Rafael Kramann and has published in prestigious journals such as PLoS ONE, Brain and The Journal of Pathology.

In The Last Decade

Hélène F.E. Gleitz

13 papers receiving 248 citations

Peers

Countries citing papers authored by Hélène F.E. Gleitz

Since Specialization

Citations

This map shows the geographic impact of Hélène F.E. Gleitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène F.E. Gleitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène F.E. Gleitz more than expected).

Fields of papers citing papers by Hélène F.E. Gleitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène F.E. Gleitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène F.E. Gleitz. The network helps show where Hélène F.E. Gleitz may publish in the future.

Co-authorship network of co-authors of Hélène F.E. Gleitz

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène F.E. Gleitz. A scholar is included among the top collaborators of Hélène F.E. Gleitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène F.E. Gleitz. Hélène F.E. Gleitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis 2025 ·HemaSphere ·Hélène F.E. Gleitz, (unknown), Inge Snoeren, Charlotte Boys, James S. Nagai, (unknown), (unknown), (unknown), (unknown), (unknown), Eric M. Bindels, Julio Sáez-Rodríguez, Thomas Vogl, Rafael Kramann, Aurélien Dugourd, Ivan G. Costa, Rebekka K. Schneider	0
2	Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy 2023 ·Molecular Therapy — Methods & Clinical Development ·Stuart Ellison, Aiyin Liao, Hélène F.E. Gleitz, Helen Parker, Laura Booth, John E. Robinson, (unknown), (unknown), Rebecca Holley, Brian Bigger	5
3	Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation 2023 ·Blood Advances ·(unknown), (unknown), Inge Snoeren, Eric M. Bindels, Stephani Schmitz, (unknown), Remco M. Hoogenboezem, (unknown), Mohamed I. Saad, Wencke Walter, Torsten Haferlach, (unknown), Julio Sáez-Rodríguez, Aurélien Dugourd, Kjong-Van Lehmann, Yinon Ben‐Neriah, Hélène F.E. Gleitz, Rebekka K. Schneider	0
4	Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II 2023 ·Human Gene Therapy ·(unknown), (unknown), Stuart Ellison, (unknown), (unknown), (unknown), Gabriella Forte, Claire O’Leary, Hélène F.E. Gleitz, Aiyin Liao, James Cook, Rebecca Holley, Brian Bigger	2
5	S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS 2023 ·HemaSphere ·Hélène F.E. Gleitz, Inge Snoeren, (unknown), James S. Nagai, Aurélien Dugourd, Charlotte Boys, (unknown), (unknown), Eric M. Bindels, (unknown), Martina Crysandt, Julio Sáez-Rodríguez, Thomas Vogl, Rafael Kramann, Ivan G. Costa, Rebekka K. Schneider	2
6	Biological drivers of clinical phenotype in myelofibrosis 2022 ·Leukemia ·John Mascarenhas, Hélène F.E. Gleitz, Helen T. Chifotides, Claire Harrison, Srđan Verstovšek, Alessandro M. Vannucchi, Raajit K. Rampal, Jean‐Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K. Schneider, Alan F. List	28
7	Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing 2021 ·STAR Protocols ·Hélène F.E. Gleitz, Inge Snoeren, (unknown), Nils B. Leimkühler, Rebekka K. Schneider	4
8	Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms 2021 ·Current Opinion in Hematology ·Hélène F.E. Gleitz, (unknown), Rebekka K. Schneider	23
9	An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA 2019 ·Human Gene Therapy ·Anna L. Gray, Claire O’Leary, Aiyin Liao, (unknown), (unknown), Hélène F.E. Gleitz, Helen Parker, (unknown), Olivier Danos, Michaël Hocquemiller, (unknown), R. Michael Linden, Els Henckaerts, Rebecca Holley, Brian Bigger	14
10	Fibrosis driving myofibroblast precursors in MPN and new therapeutic pathways 2019 ·HemaSphere ·Hélène F.E. Gleitz, (unknown), Rafael Kramann, Rebekka K. Schneider	1
11	Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms 2018 ·EMBO Molecular Medicine ·Hélène F.E. Gleitz, (unknown), James Cook, (unknown), Gabriella Forte, Zelpha D’Souza, Claire O’Leary, Rebecca Holley, Brian Bigger	68
12	Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis 2018 ·The Journal of Pathology ·Hélène F.E. Gleitz, Rafael Kramann, Rebekka K. Schneider	14
13	Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II 2017 ·PLoS ONE ·Hélène F.E. Gleitz, Claire O’Leary, Rebecca Holley, Brian Bigger	20
14	Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy 2017 ·Brain ·Rebecca Holley, Stuart Ellison, Daniel Fil, Claire O’Leary, John McDermott, (unknown), Alex Langford-Smith, Fiona L. Wilkinson, Zelpha D’Souza, Helen Parker, Aiyin Liao, (unknown), Hélène F.E. Gleitz, Shih‐hsin Kan, Patricia Dickson, Brian Bigger	66
15	Whole body correction of severe mucopolysaccharidosis type II by lentiviral-mediated stem cell gene therapy with blood-brain barrier-crossing peptides 2017 ·Molecular Genetics and Metabolism ·Hélène F.E. Gleitz, Claire O’Leary, Rebecca Holley, Brian Bigger	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact